Kitabis Pak (co-packaging of tobramycin inhalation solution and a PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

Kitabis Pak is about patient convenience, patient access, and removing issues with device access from the treatment equation. Drug + Device, Delivered together so you can start your treatments right away.* Eligible patients take advantage of our Co-Pay Assistance.

What is Kitabis Pak? Kitabis Pak is a co-packaging of Tobramycin Inhalation Solution (drug) and PARI LC PLUS ® Reusable Nebulizer (device) in a patient convenience kit. Kitabis Pak contains a prescription antibacterial medicine called tobramycin (an aminoglycoside) used to treat adults and children 6 years of age and older with cystic fibrosis ...

Please find some useful resources below that will help you gain a better understanding of Kitabis Pak. Read more about Kitabis Pak and learn how it fights bacterial infections due to Pseudomonas aeruginosa.

KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa .

Kitabis ® Pak (Ki TAH biss Pak) is a co-packaging of Tobramycin Inhalation Solution (drug) and PARI LC PLUS Reusable Nebulizer (device) in a patient convenience kit. Kitabis Pak is indicated for the management of cystic fibrosis in adults and pediatric patients 6 …

in the Kitabis Pak. The PARI LC PLUS is intended for adult and pediatric patients consistent with the indications for the Kitabis Pak. Improper use can result in serious or fatal illness or injury. Nebu-lizer is not sterile. Use only when prescribed by a physi-cian and with the prescribed medication. 1. To reduce the risk of bacterial

PARI LC PLUS® packaged with Tobramycin Inhalation Solution

KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV

References 1. Geller, D. Comparing Clinical Features of the Nebulizer, Metered-Dose Inhaler and Dry Powder Inhaler. Respir. Care 2005; 50(10):1313–1321.